Kiniksa Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $122,536 | $112,214 | $108,631 | $79,858 |
Gross Profit | 184,762 | 62,798 | 66,176 | 48,320 |
EBITDA | -18,899 | -9,658 | 313 | -16,076 |
EBIT | -19,299 | -10,057 | -117 | -16,542 |
Net Income | -8,888 | -12,693 | -3,908 | -17,704 |
Net Change In Cash | 122,536 | 112,214 | 108,631 | 79,858 |
Free Cash Flow | 18,577 | -2,236 | 5,168 | 3,903 |
Cash | 183,581 | 97,376 | 99,271 | 141,078 |
Basic Shares | 71,424 | 71,726 | 71,004 | 70,633 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $423,239 | $270,259 | $220,180 | $38,544 |
Gross Profit | 423,239 | 213,735 | 173,214 | 29,444 |
EBITDA | -45,616 | -22,855 | 9,773 | -154,281 |
EBIT | -25,196 | 5,553 | -156,636 | |
Net Income | -43,193 | 14,084 | 183,363 | -157,924 |
Net Change In Cash | 423,239 | 270,259 | 220,180 | 38,544 |
Cost of Revenue | 245 | 8,222 | ||
Free Cash Flow | 25,412 | 13,171 | 5,702 | -146,713 |
Cash | 183,581 | 107,954 | 122,715 | 122,470 |
Basic Shares | 71,424 | 71,922 | 70,421 | 68,576 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.12 |
2024-09-30 | -$0.18 |
2024-06-30 | -$0.06 |
2024-03-31 | -$0.25 |
